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Autosomal recessive polycystic kidney disease (ARPKD) is a rare monogenic disease 
with a severe phenotype often presenting prenatally or in early childhood. With its 
obligate renal and hepatic involvement, ARPKD is one of the most important indications 
for liver and/or kidney transplantation in childhood. Marked phenotypic variability is 
observed, the genetic basis of which is largely unknown. Treatment is symptomatic 
and largely empiric as evidence-based guidelines are lacking. Therapeutic initiatives for 
ARPKD face the problem of highly variable cohorts and lack of clinical or biochemical 
risk markers without clear-cut clinical end points. ARegPKD is an international, 
multicenter, retro- and prospective, observational study to deeply phenotype patients 
with the clinical diagnosis of ARPKD. Initiated in 2013 as a web-based registry (www.
aregpkd.org), ARegPKD enrolls patients across large parts of Europe and neighboring 
countries. By January 2017, more than 400 patients from 17 mostly European countries 
have been registered in the ARPKD registry study with significant follow-up data. Due 
to comprehensive retro- and prospective data collection and associated biobanking, 
ARegPKD will generate a unique ARPKD cohort with detailed longitudinal clinical 
characterization providing a basis for future clinical trials as well as translational research. 
Hence, ARegPKD is hoped to contribute to the pathophysiological understanding of 
the disease and to the improvement of clinical management.
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BAcKGrOUND
Autosomal recessive polycystic kidney disease (ARPKD) is a severe form of polycystic kidney 
disease with early manifestation and substantial morbidity and mortality. ARPKD constitutes 
one of the most important causes of renal replacement therapy and/or liver transplantation in 
childhood. Hence, the disease has substantial socioeconomic impact despite its low incidence 
(1  in 20,000  live births) (1).
Autosomal recessive polycystic kidney disease is caused by mutations in a single gene, polycystic 
kidney and hepatic disease 1 (PKHD1), encoding the ciliary protein fibrocystin/polyductin (2). 
Fibrocystin is a very large protein with a single transmembrane domain and a short cytoplasmatic 
part (2). Fitting to the ciliary hypothesis (3) and the obligate renal and hepatic phenotype, fibrocystin 
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is expressed in primary cilia of renal and bile duct epithelial cells 
(4, 5). Fibrocystin seems to exert some effects via the same intra-
cellular signaling pathways which are also dysregulated in the 
closely related autosomal dominant polycystic kidney disease 
(ADPKD) (6, 7), but the specific mechanisms leading to cysts 
and the peculiar clinical phenotype of the disease are still to be 
identified and described in detail.
The phenotypic spectrum of ARPKD is broad, even within 
affected families (8, 9). The disease is associated with bilateral 
ubiquitous fusiform dilatations of the collecting duct, leading 
to multiple very small cysts and a massive increase of kidney 
volume. Unlike in ADPKD, no clear correlation between kidney 
volume and the decline of kidney function over time has been 
observed (10–12). Despite massive growth of kidneys that can 
occur even before birth, renal function is frequently preserved 
over several months or even years. In patients with prenatally 
impaired renal function, oligohydramnios may lead to pulmo-
nary hypoplasia with associated pulmonary hypertension. These 
patients suffer from significant morbidity and mortality. Other 
patients show late disease onset with a predominantly hepatic 
phenotype and preserved renal function until adolescent or even 
adult age (9, 13).
The genotype–phenotype correlation is currently refined to 
the observation that patients with two truncating mutations in 
PKHD1 show a severe phenotype with common perinatal demise, 
whereas children surviving the postnatal period carry at least one 
missense mutation (9). However, severe courses have also been 
described with missense mutations. Interpretation is hampered 
by the big size of the gene with 67 exons and a complex splicing 
pattern, the absence of a mutational hotspot, and the multiple 
private mutations, detected only within individual families. 
More than 700 variations have been described and classified in 
the PKHD1 mutation database (www.humgen.rwth-aachen.de/
index.php).
Remarkably, even up to 20% of siblings show marked variance 
in phenotype (9), indicating that the genotype alone is not suf-
ficient to explain the phenotypic variability in ARPKD (9, 14). 
The genetic basis for the large inter- and intrafamiliar phenotypic 
variability is poorly understood. Epigenetic and environmental 
factors as well as variations in other ciliopathy or PKD genes 
have been suggested (9, 10, 15). However, no genetic, clinical, 
or biochemical risk markers predicting disease progression or 
severity have been identified to date.
The treatment of renal insufficiency, arterial and pulmonary 
hypertension as well as the management of the hepatic phenotype 
with congenital hepatic fibrosis, portal hypertension, and chol-
angitis are largely symptomatic and opinion based, relying on 
expert recommendations (16). Disease-specific causative treat-
ment options are still lacking, despite tremendous progress in 
our understanding of ciliary pathomechanisms (17–19). Targeted 
treatment approaches have emerged for ADPKD (20–25), but 
the ADPKD trial findings cannot readily be extrapolated to 
ARPKD. Despite the much more severe phenotype of ARPKD 
with progression to end-stage renal disease of the majority of 
the patients within the first two decades of life (9) [as compared 
to 58.1 years (PKD1) and 79.9 years (PKD2) in ADPKD (26)], 
the large individual phenotypic variability and the 40-fold lower 
incidence of ARPKD relative to ADPKD have so far precluded the 
development of clinical trial programs to evaluate the usefulness 
of compounds interfering with cyst growth.
Several landmark studies, e.g., by Guay-Woodford and 
Desmond (27), Bergmann et al. (9), and Adeva et al. (13), have 
described the clinical course of individuals with ARPKD in 
European and North American cohorts. Despite these excellent 
previous works, numerous questions remain regarding long-
term clinical outcomes, the relative efficacy of current symp-
tomatic treatment approaches, and the most suitable criteria to 
define risk-based cohort stratification in future interventional 
trials.
To tackle these questions and challenges, the ARegPKD 
registry study was recently initiated by the German Society 
for Pediatric Nephrology (GPN) and the European Study 
Consortium for Chronic Kidney Disorders Affecting Pediatric 
Patients Network (ESCAPE-Network). Here, we report about 
the current state of progress of this study.
DesiGN
ARegPKD is an international, multicenter, and observational 
study that follows both pediatric and adult patients with the 
clinical diagnosis of ARPKD (28).
Diagnostic criteria are (a) typical findings on renal imaging 
and (b) one or more of the following criteria:
• Clinical/laboratory signs of hepatic fibrosis
• Hepatic pathology demonstrating ductal plate abnormality
• Absence of renal enlargement and/or multiple cysts in both 
parents
• Pathoanatomic diagnosis of ARPKD in an affected sibling
• Family history consistent with autosomal recessive inheritance.
Exclusion criteria encompass definite genetic, histological, or 
clinical proof of other cystic kidney disorders.
Deep phenotypic characterization is ensured by entry of 
basic data and both retro- and prospective visits. Basic data 
encompass age and clinical symptoms at primary manifesta-
tion as well as perinatal period, genetic testing, and family 
history. Date of diagnosis and criteria leading to diagnosis are 
checked for plausibility with other entries. The visits (initial 
visit/follow-up visits) can be entered retro- and prospectively 
thereby also enabling inclusion of deceased pediatric patients in 
order to counteract the problem of underreporting of severely 
affected and early deceased patients. Visits are planned to 
be entered annually but can be documented at flexible time 
intervals, e.g., using longer intervals for retrospective entry of 
adult patients but more frequent prospective data entries of 
incident patients. In this way, detailed longitudinal information 
is provided over decades of patient follow-up for the following 
type of information:
• Patient status—baseline evaluation (e.g., body measurements, 
participation in studies, availability of biosamples)
• Renal status including symptoms, radiological findings, and 
biopsy results
FiGUre 1 | registered centers (A) and included number of patients (B). Number of included patients from different countries (c).
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• Extrarenal status regarding liver (symptoms, radiological 
findings, biopsy results) and other organs (spleen, cardio-
vascular system, central nervous system, eyes, lungs, bones, 
blood)
• Laboratory values
• Medications with start and end date, dose
• Therapy including renal replacement therapy, surgical proce-
dures, and other procedures
• Further developments (symptoms, performed diagnostic 
procedures, any additional information) with inclusion of 
user-defined comments.
Pseudonymized data are entered into a password-restricted, 
web-based database (www.aregpkd.org) by authorized medical 
personnel. Subject pseudonymization is performed at the cor-
responding center.  The database is stored on a safe server of 
the Cologne University Computing Facilities and secured by 
use of SSL connections.
Given the heterogeneity of the patient cohort and the variety 
of entering individuals, automatic checks for coherence, plau-
sibility, and validity were installed according to a detailed data 
validation plan. Erroneous entries are recognized by application 
of predefined plausibility ranges for measurements, laboratory 
values, and medication doses. Queries are sent to local investiga-
tors in order to complete data and solve plausibility problems or 
discrepancies.
The clinical documentation is complemented by prospective 
collection and storage of biomaterials in a central biorepository. 
Coded samples are stored at the Hannover Unified Biobank at 
Hannover Medical School, one of the most advanced biobanks in 
Europe with high quality and safety standards. Consent process 
is complete for a large number of research approaches. For any 
specific subsequent study, this question will be re-evaluated by 
the study consortium coordinators and, where necessary, a cor-
responding ethics committee.
Reference histopathology of biopsy samples is offered at the 
University Hospital of Cologne by an internationally recognized 
expert for ARPKD.
The study protocol has been approved by the Ethics 
Commission of the Faculty of Medicine of Cologne University 
and the Institutional Review Boards of each participating site.
Statistical analysis is performed by a biostatistician of the 
Institute of Medical Biometry and Informatics, University of 
Heidelberg, according to a statistical analysis plan defining the 
detailed descriptive analysis of the clinical courses, the identifi-
cation of clinical risk factors, and the evaluation of therapeutic 
approaches.
Researchers, both those who are currently engaged in the 
registry and external investigators, are encouraged to approach 
the study consortium coordinators for collaborations with a spe-
cific research question that will be discussed during the regular 
consortium meetings.
Patients and participating centers can continuously follow the 
progress of recruitment for the registry on the public webpage. 
There is furthermore a regular newsletter on ARegPKD and PKD 
aspects in general that is sent to the specific centers, which can be 
passed on to patients or can be downloaded from the ARegPKD 
webpage.
cUrreNt stAtUs
Data entry started in July 2013. Currently, 93 centers from 
23 mostly European countries have registered for the study 
(Figure 1A). By January 2017, 403 patients have been included 
(Figure  1B) at 57 centers in 17 countries. Data from eight 
patients were excluded as patients did not fulfill the inclusion 
criteria, resulting in data from 395 patients for evaluation. This 
includes more than 60 adult patients. The largest patient num-
bers have been enrolled at centers in Germany, Poland, Turkey, 
and the United Kingdom (Figure  1C). While the majority of 
patients are currently followed in pediatric nephrology divi-
sions, a substantial number has also been recruited by pediatric 
gastroenterologists or hepatologists. By January 2017 data 
from more than 1,700 visits of 364 patients has been collected 
(Figures 2A,B). To the best of our knowledge, ARegPKD thus 
represents the largest multinational cohort of ARPKD patients 
with available detailed clinical data.
Due to enrollment in 17 European and neighboring coun-
tries with a cumulative population of more than 300 million 
people, ARegPKD is gathering a substantial number of ARPKD 
patients, despite the low incidence of the disease. In addi-
tion to answering important questions regarding the natural 
FiGUre 2 | Number of documented visits (A) and number of visits per patient (B).
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history of the disease, the international data collection allows 
a Pan-European reflection on the role of different health-care 
structures, management approaches, and the large variation in 
genetic endowment.
Following up patients to adulthood, ARegPKD will provide 
substantial information regarding the long-term evolution of both 
early- and late-onset disease. This will allow to address important 
questions that require observation of disease courses over dec-
ades, such as: What are the consequences of early nephrectomy 
in ARPKD? Does the stringency of blood pressure control influ-
ence renal function loss over time? Is the preservation of kidney 
function differently affected by the type of antihypertensive 
drugs used? How do extrarenal phenotypes develop? What is 
the relationship between the renal and the hepatic phenotype 
in ARPKD? Are there clinical, genetic, or biochemical markers 
to predict the disease course and to support decision making 
regarding isolated, combined, and/or sequential liver and kidney 
transplantation? Are there differences in the management of vari-
ous disease aspects between regions or countries?
The implementation of comprehensive genotyping will 
allow the assessment of genotype–phenotype correlations in 
this clinically deeply characterized cohort. ARegPKD is closely 
connected to the Network for Early Onset Cystic Kidney Disease 
(NEOCYST) consortium, in which clinicians, geneticists, and 
basic scientists have teamed up to study the clinical and genetic 
overlap of cystic kidney diseases and establish guidelines for 
diagnostics and standards of care. Within the frame of NEOCYST 
ARegPKD will also be evaluated by an external advisory board.
The focus and strength of the ARegPKD registry study lies on 
the stringent collection of detailed longitudinal data in a large 
patient cohort, which will allow to outline the natural course of 
the disease and to identify prognostically uniform subcohorts 
of this heterogeneous disease. Given the observational design of 
the study, there are obvious weaknesses which include selection 
bias, incomplete data collection, and operator-dependency of 
sonographic findings. Yet, the data collected truly represent the 
“real-life” situation of patients with ARPKD followed in major 
clinical centers.
In summary, since its start in 2013, ARegPKD has made 
substantial progress with successful international recruitment 
of ARPKD patients. Given this progress, ARegPKD will soon 
provide an observational evidence base to recommendations for 
the care of patients suffering from ARPKD.
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